Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CRVS | Common Stock | Purchase | $34.6K | +20K | +14.95% | $1.73 | 154K | May 6, 2024 | Direct |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CRVS | Warrant (Right to Buy) | Purchase | +19.4K | 19.4K | May 6, 2024 | Common Stock | 19.4K | $3.50 | Direct | F1 |
Id | Content |
---|---|
F1 | Issued at no additional consideration to the Reporting Person in connection with their subscription for shares of the Issuer's Common Stock at a price of $1.7312. |
SVP, Pharmaceutical Development